APA (7th ed.) Citation

Tolaney, S. M., de Azambuja, E., Kalinsky, K., Loi, S., Kim, S., Yam, C., . . . Schmid, P. (2026). Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 394(4), 354. https://doi.org/10.1056/NEJMoa2508959

Chicago Style (17th ed.) Citation

Tolaney, S. M., et al. "Sacituzumab Govitecan Plus Pembrolizumab for Advanced Triple-Negative Breast Cancer." New England Journal of Medicine 394, no. 4 (2026): 354. https://doi.org/10.1056/NEJMoa2508959.

MLA (9th ed.) Citation

Tolaney, S. M., et al. "Sacituzumab Govitecan Plus Pembrolizumab for Advanced Triple-Negative Breast Cancer." New England Journal of Medicine, vol. 394, no. 4, 2026, p. 354, https://doi.org/10.1056/NEJMoa2508959.